Switchers, apply here, says HPRA
This article was originally published in OTC Bulletin
Executive Summary
Irish medicines agency, the HPRA, has said it is “open” to prescription-to-OTC switch applications, especially if they are first-in-category switches, and will offer advice to firms that apply.
You may also be interested in...
Post-Switch Market Exclusivity Benefits Everyone, Insists Global Switch Expert
Three- to five-year market exclusivity periods for switched products would not only incentivize consumer healthcare firms but also enable pre- and post-switch data to be generated more easily, thus improving the quality of switch applications, explains global switch expert Dr Natalie Gauld in the final part of our exclusive interview.
Second Time Lucky? Sumatriptan One Of Three Switches On The Cards In Germany
A second attempt at switching sumatriptan for migraines, as well as switch applications for non-steroidal anti-inflammatories ketoprofen and liquid ibuprofen, are all on the agenda at Germany's next Expert Committee for Prescription meeting in June.
An Expert’s Guide To Switching In Germany, Part 2: Improving The Reclassification Process
In Part 2 of this exclusive interview, Elmar Kroth, scientific director of the German Medicines Manufacturers´ Association, the BAH, tells HBW Insight what the association is doing to improve the prescription-to-OTC switch process in Germany.